替雷利珠单抗注射液致免疫相关性糖尿病1例  

A case of immune-related diabetes caused by tislelizumab injections

作　　者：柏越 魏丹[2] 张伟[2] 廖琳[2] 朱夷凡 史永昊 董中华 李妍[5] BAI Yue;WEI Dan;ZHANG Wei;LIAO Lin;ZHU Yifan;SHI Yonghao;DONG Zhonghua;LI Yan(Department of Pharmacy,Jinan Jiyang District Hospital of Traditional Chinese Medicine,Shandong Jinan 251400,China;Department of Endocrinology and Metabolism,the First Affiliated Hospital of Shandong First Medical University,Shandong Provincial Qianfoshan Hospital,Shandong Jinan 250014,China;Department of Pharmacy,the Third People’s Hospital of Jingdezhen,Jiangxi Jingdezhen 333000,China;Department of Pharmacy,Linzi District Maternal and Child Health Hospital,Qidu Hospital,Shandong Zibo 255400,China;Department of Clinical Pharmacy,the First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Shandong Medicine and Health Key Laboratory of Clinical Pharmacy,Shandong Jinan 250014,China)

机构地区：[1]济南市济阳区中医医院药剂科,山东济南251400 [2]山东第一医科大学第一附属医院,山东省千佛山医院内分泌病学与代谢病学科,山东济南250014 [3]江西省景德镇市第三人民医院药剂科,江西景德镇333000 [4]山东省淄博市临淄区妇幼保健院,齐都医院药剂科,山东淄博255400 [5]山东第一医科大学第一附属医院/山东省千佛山医院临床药学,山东省医药卫生重点实验室,山东济南250014

出　　处：《中国医院药学杂志》2025年第7期845-847,共3页Chinese Journal of Hospital Pharmacy

摘　　要：替雷利珠单抗是一种抗PD-1免疫检查点抑制剂,广泛应用于多种肿瘤的免疫治疗中,其可能引发免疫相关性不良反应,免疫相关性糖尿病为罕见但严重的并发症之一,发病迅速且不可逆,通常伴随糖尿病酮症酸中毒的急性发作。该文报道1例替雷利珠单抗注射液致免疫相关性糖尿病的病例,通过分析现有文献和临床案例,总结替雷利珠单抗引发免疫相关性糖尿病的临床特征,探讨免疫检查点抑制剂致糖尿病不良反应机制与处理、药学监护,以期在临床使用中警惕抗PD-1免疫检查点抑制剂引起的免疫相关性糖尿病。Tislelizumab is an anti-programmed cell death-1(PD-1)immune checkpoint inhibitor that is widely used in the immunotherapy against tumors.It may cause immunerelated adverse reactions.Immune-related diabetes is one of the rare but serious complications of tislelizumab injections,with rapid and irreversible onset,and is often accompanied by acute attacks of diabetic ketoacidosis.This article reported a case of immune-related diabetes caused by tislelizumab injections.By analyzing the existing literatures and clinical cases,the clinical characteristics of immune-related diabetes caused by tislelizumab injections were summarized,and the mechanism and management of adverse events of diabetes caused by immune checkpoint inhibitors and pharmaceutical care were discussed,in order to alert immune-related diabetes caused by anti-PD-1 immune checkpoint inhibitors in clinical use.

关 键 词：替雷利珠单抗 免疫相性糖尿病 药学监护 

分 类 号：R979.5[医药卫生—药品]